Serum interleukin-18: A novel prognostic indicator for acute respiratory distress syndrome

The aim of this study is to determine the biological function of serum interleukin-18 (IL-18) on prognosis in acute respiratory distress syndrome (ARDS). From October 2016 to September 2017, 150 patients with ARDS in the ICU were enrolled according to the Berlin 2012 definition. The enzyme-linked immunosorbent assay (ELISA) was used to detect the expression level of IL-18 in serum isolated from the patients. Patients were divided into survival group (82 cases) and non-survival group (68 cases) and followed up for at least 2 months. The serum IL-18 expression level on the prognosis was calculated by receiver operating characteristic curve (ROC). The expression level of serum IL-18 was significantly higher in the non-survival group than that in the survival group (P < .05). Based on the ROC curve, the sensitivity and specificity of IL-18 as a predictor of prognosis at a cutoff of 509.5 pg/mL were 88% and 82%, respectively, and the area under the curve (RUC) was 0.84 (P < .05). The expression level of serum IL-18 could be used to evaluate the possible outcomes of patients with ARDS.